Alzheimer's disease

It's an n=1 case report from a three-person group in São Paulo, in a journal some researchers list as predatory. The patient, an octogenarian, got 5 grams then 3 grams; improvements were real but transient.

A McGill/MILA postdoc supplied the context the headline omits: case studies are among the easiest journal outputs to fabricate, and this publisher once ran an AI-generated anatomical figure of a rat that became a scientific punchline.

The compound has already passed safety evaluations for other diseases, which the release frames as a fast path to human trials. The first reply set the tone: 'Great news! If you are a mouse.'

The real reversal is the science underneath. A developer quoted chemist Derek Lowe's verdict that amyloid-directed therapies 'truly, truly do not appear to be the answer' — and a son caring for a parent with the disease explained why amyloid removal hasn't stopped decline.